# Treatments for Alzheimer
Cognitive supportive medications
The so-called cholinesterase inhibitors are medications that protect a certain signaling substance in the brain. In Alzheimer, the level of acetylcholine, a substance important for memory and attention, declines. These medications slow that breakdown process.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Donepezil, rivastigmine and galantamine are usually recommended for mild to moderate cognitive decline. They can prevent memory from deteriorating faster for several months to a year, although this effect is modest. Many people notice that their mental function remains somewhat more stable or the decline is slower. Known side effects are nausea, diarrhea, fatigue and sometimes also bradycardia (slow heart rate). These side effects are usually temporary when the body adjusts to the medication.
Memantine works on a different principle: it inhibits excessive activity of another signaling substance (glutamate) that can cause damage in Alzheimer. This medication is mainly used in moderate to advanced stages. Side effects are usually mild: headache, dizziness or confusion, which usually subside.
Amyloid-directed antibodies (monoclonal antibodies)
An important development in recent years are medications that target amyloid-beta, a protein that accumulates in the brain and is seen as a key player in Alzheimer.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Aducanumab and lecanemab are antibodies that have been approved for intravenous administration in patients with mild cognitive impairment or mild dementia with confirmed amyloid pathology. They reduce the amount of amyloid in the brain and can delay cognitive decline by several months. An important risk is amyloid-related imaging abnormalities (ARIA): microinfarcts or microhemorrhages visible on MRI. This occurs in some treated individuals and can cause headaches, confusion or visual changes. Regular neuroimaging is therefore necessary. Infusions are usually given weekly or biweekly and require medical supervision.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Donanemab is another antibody against amyloid that was more recently approved. It is also given intravenously and works similarly, with the same precautions regarding ARIA.
Tau-directed medications
Tau is another harmful protein that accumulates in Alzheimer. Multiple studies are underway into medications that target this substance.
ResearchediPositive results in clinical studies, not yet standard treatment
Various small molecules and antibodies against tau are in clinical trials. Some promising candidates are still under investigation and are not yet approved. Studies suggest that inhibitors of certain enzymes (kinases) that damage tau may be effective in slowing symptoms.
Anti-inflammatory and immunomodulatory agents
Recent findings point to a role of chronic inflammation and immune activity in Alzheimer. Microglial cells (immune cells in the brain) play a key role in this.
ResearchediPositive results in clinical studies, not yet standard treatment
Various substances are being studied that better balance the immune response in the brain, such as inhibitors of certain signaling pathways (for example kinase inhibitors targeting microglial cells). Research is also looking at nonsteroidal anti-inflammatory drugs, although to date no clear benefits have been shown for Alzheimer itself.
Antioxidants and neuroprotectors
Oxidative stress (excess free radicals in cells) contributes to brain cell damage in Alzheimer.
ResearchediPositive results in clinical studies, not yet standard treatment
Vitamins (especially vitamins E and B), coenzyme Q10 and other antioxidants are being studied in larger trials. To date they show modest effects in smaller studies, but do not actually prevent cognitive decline in large randomized trials.
UnproveniNo scientific evidence that it works
Many supplements and herbal remedies (ginkgo, turmeric/curcumin, etc.) are promoted, but lack strong scientific support for effectiveness against Alzheimer. They should not be seen as a replacement for proven therapies.
Lifestyle interventions and cognitive training
A growing number of studies show that certain lifestyle changes can reduce the risk of cognitive decline, especially in early stages.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular physical activity (especially aerobic exercise), a healthy diet (especially the MIND or Mediterranean diet), cognitive exercise (puzzles, reading, brain training), social engagement, and good sleep are supported by extensive research as protective. These measures require no medications, but do require consistency and guidance. Many memory clinics and day programs offer these trainings.
Sleep treatment
Poor sleep is associated with faster cognitive decline and amyloid buildup.
ResearchediPositive results in clinical studies, not yet standard treatment
Treating sleep disorders (obstructive sleep apnea, insomnia) may potentially be beneficial. Medications for this (mild sleep-inducing, such as melatonin or certain sleeping pills) are used cautiously because some can actually worsen confusion. Sleep hygiene (regular sleep schedule, dark bedroom, no screens before bed) is a first step.
Blood pressure and metabolic control
High blood pressure and diabetes are associated with Alzheimer risk.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Aiming for good blood pressure control (especially in middle age and early old age) and blood sugar management may help slow Alzheimer's. These fall under regular medical care and are not Alzheimer-specific, but are relevant for overall brain protection.
Hormonal therapies
This is a controversial topic.
UnproveniNo scientific evidence that it works
Estrogen replacement therapy in women was once proposed for prevention, but recent large studies have not confirmed this. This is no longer routinely recommended to prevent Alzheimer's.
Future approaches in research
ExperimentaliOngoing in study setting, outcome still unknown
Dozens of studies worldwide are exploring new approaches: other amyloid- and tau-targeted drugs, immune modulators, mitochondrial protectors, and gut flora interventions (probiotics, bacterial metabolites). Artificial intelligence is also being investigated for early detection of risks and prognosis. These interventions are not yet available outside research settings.
---
*This information never replaces the judgment of a doctor. Always discuss your situation with your own healthcare provider.*